Drug intelligence / Profile preview

H-biota Digest

Development stage: Unknown
Lead developer: AB-BIOTICS
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

H-biota Digest is an over-the-counter probiotic dietary supplement developed by Almus Pharma in partnership with AB-Biotics. It is formulated to support gut health, address intestinal dysbiosis, and manage diarrhea. The product contains a patented combination of three probiotic strains—Lactobacillus rhamnosus GG ATCC 53103, Bifidobacterium longum KABP 042 (CECT 7894), and Pediococcus pentosaceus KABP 041 (CECT 8330)—synergistically combined with the prebiotic inulin and zinc citrate. These components work together to inhibit enteric pathogens, restore healthy gut microbiota, and support immune function.

Brand names: H-biota Digest
Other names: Ейч-биота Дайджест

Beyond the preview

Go deeper on H-biota Digest.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H-biota Digest.

Explore the full profile